Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Hematologic Neoplasms 4Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lung Neoplasms 1Hypogonadism 1Hematopoietic and Lymphatic System Neoplasm 1Heart Failure 1Colitis 1Central Nervous System Neoplasms 1Cardiomyopathies 1Carcinoma, Non-Small-Cell Lung 1Anemia, Aplastic 1

Interventions

Temozolomide 30Radiotherapy 23Filgrastim 12Carmustine 12Irinotecan 11Carboplatin 11Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Etoposide 7Surgical Procedures, Operative 6Magnetic Resonance Spectroscopy 6Vincristine 5Peripheral Blood Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5sargramostim 4motexafin gadolinium 4Topotecan 4Thiotepa 4Paclitaxel 4Melphalan 4Gene Expression Profiling 4Gemcitabine 4Drug Therapy 4Busulfan 4temsirolimus 3etoposide phosphate 3Specimen Handling 3Mass Spectrometry 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Central Nervous System Neoplasms × Practice Guidelines as Topic × Clear all
NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Mayo Clinic

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡